Quarterly report pursuant to Section 13 or 15(d)

Supplemental Disclosure for Statements of Cash Flows (Details)

v3.3.0.814
Supplemental Disclosure for Statements of Cash Flows (Details) - USD ($)
1 Months Ended 9 Months Ended
Mar. 31, 2015
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Supplemental Disclosure For Statements Of Cash Flows [Line Items]        
Cash paid during the period for interest   $ 3,300,000 $ 2,100,000  
End-of-term fee   1,000,000 $ 2,400,000  
Derivative liabilities   63,000   $ 0
Deemed dividend on beneficial conversion feature of MT Preferred Stock   $ 46,000    
Convertible Preferred Stock        
Supplemental Disclosure For Statements Of Cash Flows [Line Items]        
Deemed dividend on beneficial conversion feature of MT Preferred Stock $ 46,000      
Macrophage Therapeutics | Convertible Preferred Stock        
Supplemental Disclosure For Statements Of Cash Flows [Line Items]        
Deemed dividend on beneficial conversion feature of MT Preferred Stock $ 46,000